NDUFV3
ENSG00000160194
Target class
Enzyme
Chromosome
21
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Other names
- CI-10k
- Target name
- NDUFV3
- Gene name
- NADH:ubiquinone oxidoreductase subunit V3
- Gene symbol
- NDUFV3
- Protein name
- NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial (Complex I-9kD) (CI-9kD) (NADH-ubiquinone oxidoreductase 9 kDa subunit) (Renal carcinoma antigen NY-REN-4)
- Gene biotype
- Protein coding
- Gene family
- NADH:ubiquinone oxidoreductase supernumerary subunits
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 27.08
- Tissue specificity (Gini)
- 0.154
- Tissue specificity (tau)
- 0.497
- KEGG gene identifiers
- hsa:4731
- Protein interaction confidence
- 0.938268
- Protein interaction partners
- 82
- R-HSA-611105
- R-HSA-6799198
- R-HSA-9837999
- End position
- 42913304
- Start position
- 42879644
- Chromosome
- 21
- Strand
- Forward
- Mitochondrion inner membrane
- Peripheral membrane protein
- Matrix side .
- Mitochondria
Publication evidence
- PubMed 12611891
- Tissue specificity (tau)
- 0.49692
- Expression inequality (Gini)
- 0.154083
Expression in transcripts per million
- Muscle - Skeletal
- 27.08
- Testis
- 22.71
- Heart - Left Ventricle
- 20.13
- Esophagus - Muscularis
- 19.93
- Heart - Atrial Appendage
- 19.29
Expression in transcripts per million
- Muscle - Skeletal27.08
- Testis22.71
- Heart - Left Ventricle20.13
- Esophagus - Muscularis19.93
- Heart - Atrial Appendage19.29
- Colon - Sigmoid18.53
- Esophagus - Gastroesophageal Junction18.22
- Nerve - Tibial17.59
- Brain - Cerebellar Hemisphere17.52
- Cells - Cultured fibroblasts17.29
- Pituitary16.65
- Uterus16.44
- Fallopian Tube16.39
- Thyroid16.09
- Ovary16.06
- Prostate15.5
- Brain - Cerebellum15.41
- Cervix - Endocervix15.12
- Artery - Tibial15.06
- Adipose - Subcutaneous15.02
- Artery - Coronary14.51
- Cervix - Ectocervix14.49
- Skin - Sun Exposed (Lower leg)14.27
- Bladder14.07
- Adipose - Visceral (Omentum)13.81
And 29 more, listed on the interactive page.
- GO:0006120
- GO:0042775
- GO:0005739
- GO:0005743
- GO:0045271
- GO:0003723
- GO:0005515
- GO:0008137
Related records
Trials (2,107)
- "Hepatic Substrate Flux Rates in Type 2 Diabetes"
- "MetCool ACS"- Metformin "Cooling" Effect on Metformin-naive Patients Treated With PCI Because of Acute Coronary Syndrome
- 1% Metformin Gel in the Treatment of Class II Furcation Defects
- 1% Metformin in Moderate and Severe Periodontitis
- 12 Weeks Treatment With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
- 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
- 30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)
- 52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
- A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
- A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
- A Bioequivalence Study Of Ethinylestradiol + Gestodene In Female And Healthy Volunteers.
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants
- A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration
Drugs (4)
- ME-344 Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin Mitochondrial complex I (NADH dehydrogenase) inhibitor
- Metformin hydrochloride Mitochondrial complex I (NADH dehydrogenase) inhibitor
- NV-128 Mitochondrial complex I (NADH dehydrogenase) inhibitor